Corvus Pharmaceuticals, Inc. financial data

Symbol
CRVS on Nasdaq
Location
Burlingame, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 396% % 105%
Debt-to-equity 28% % -49%
Return On Equity -26% % 85%
Return On Assets -20% % 81%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74,681,872 shares 16%
Common Stock, Shares, Outstanding 74,681,872 shares 19%
Entity Public Float $69,000,000 USD -18%
Common Stock, Value, Issued $7,000 USD 17%
Weighted Average Number of Shares Outstanding, Basic 82,836,369 shares 24%
Weighted Average Number of Shares Outstanding, Diluted 82,836,369 shares 24%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $29,754,000 USD 71%
General and Administrative Expense $9,105,000 USD 18%
Operating Income (Loss) $38,859,000 USD -55%
Nonoperating Income (Expense) $415,000 USD
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $15,075,000 USD 73%
Earnings Per Share, Basic 0 USD/shares 74%
Earnings Per Share, Diluted 0 USD/shares 37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,867,000 USD -39%
Cash, Cash Equivalents, and Short-term Investments $65,700,000 USD 58%
Accounts Receivable, after Allowance for Credit Loss, Current $32,000 USD -54%
Other Assets, Current $509,000 USD -20%
Assets, Current $66,944,000 USD 56%
Property, Plant and Equipment, Net $221,000 USD 29%
Operating Lease, Right-of-Use Asset $927,000 USD 226%
Other Assets, Noncurrent $852,000 USD 238%
Assets $80,474,000 USD 37%
Accounts Payable, Current $1,974,000 USD 5.4%
Employee-related Liabilities, Current $610,000 USD -19%
Accrued Liabilities, Current $5,721,000 USD
Liabilities, Current $8,074,000 USD -83%
Operating Lease, Liability, Noncurrent $632,000 USD
Liabilities $8,706,000 USD -81%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,060,000 USD -44%
Retained Earnings (Accumulated Deficit) $399,972,000 USD -3.9%
Stockholders' Equity Attributable to Parent $71,768,000 USD 478%
Liabilities and Equity $80,474,000 USD 37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,263,000 USD -60%
Net Cash Provided by (Used in) Financing Activities $279,000 USD
Net Cash Provided by (Used in) Investing Activities $4,243,000 USD
Common Stock, Shares Authorized 290,000,000 shares 0%
Common Stock, Shares, Issued 74,681,872 shares 19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,741,000 USD 28%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,867,000 USD -39%
Deferred Tax Assets, Valuation Allowance $90,533,000 USD 9.1%
Deferred Tax Assets, Gross $90,885,000 USD 9.1%
Operating Lease, Liability $354,000 USD
Payments to Acquire Property, Plant, and Equipment $36,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $15,397,000 USD 73%
Lessee, Operating Lease, Liability, to be Paid $358,000 USD
Property, Plant and Equipment, Gross $2,843,000 USD -41%
Operating Lease, Liability, Current $379,000 USD 7.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 50%
Deferred Tax Assets, Operating Loss Carryforwards $64,080,000 USD 8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $157,000 USD -67%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $22,000 USD -4.3%
Share-based Payment Arrangement, Expense $4,569,000 USD 65%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%